The abstract is read at the publisher; the summary is JClub's.
Mezigdomide treatment of ex vivo generated exhausted T cells in multiple myeloma is linked to decreased exhaustion-marker expression and increased proinflammatory cytokine expression.
- Why it matters: T-cell exhaustion is a key resistance mechanism limiting T-cell engager efficacy in multiple myeloma, and the roles of IKZF1/IKZF3 in maintaining exhaustion needed mechanistic clarification.
- What they did: The study performed extensive transcriptomic and epigenetic profiling of ex vivo generated exhausted T cells (Tex) versus their autologous activated T cells, then tested mezigdomide effects and combined therapy with alnuctamab.
- The result: In Tex, mezigdomide decreased exhaustion-related markers, increased proinflammatory cytokines, and enhanced target cell killing with alnuctamab, supporting combining mezigdomide with T-cell engagers in MM.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access